ArteraAI

ArteraAI is happy to announce that the #ArteraAI Prostate Test is the First-and-Only Predictive Test for Therapy Personalization in the 2024 National Comprehensive Cancer Network? (NCCN?) Guidelines? for Prostate Cancer. Our test is the only test included for its predictive performance, and also the first AI-enabled predictive and #prognostic test to be recommended in the guidelines for localized #prostatecancer. This is an exciting step forward for ArteraAI. As Andre Esteva, PhD, CEO and Co-Founder of ArteraAI said, “This significant milestone not only celebrates ArteraAI's success but also paves the way for the integration of AI-enabled solutions into clinical practice, illustrating their potential to enhance personalized patient care.” Read the announcement here:

That’s a wrap on ACRO - American College of Radiation Oncology Radiaton Oncology Summit! The #ArteraAI team had a great time connecting with #radonc experts, exchanging insights, and discussing the future of treatment in #prostatecancer. We look forward to continuing the conversation on AI-driven advancements in urologic care. #ACRO2025 #ArteraOnTheGo

"I think the sweet spot here really is that intermediate risk patient population. It's where the brackish waters are. We don't really know which way to go. So I think it's important to have more data points to help us determine what the next steps are." – Dr. Nitin Yerram, M.D. Did you miss our February product webinar? Watch the replay here to learn about how the #ArteraAI Prostate Test is being utilized by #urologists and #radoncs across the country to optimize cancer care: https://heyor.ca/LZZAPH Tim Showalter Peter Fried

The #ArteraAI Prostate Test assists clinicians in delivering personalized treatment for #prostatecancer. By analyzing biopsy images and clinical data, it predicts whether a patient is likely to benefit from therapy, enabling you to make better-informed decisions. With rapid insights, you can optimize treatment strategies based on individual patient needs. This personalized approach not only enhances patient care but also reduces the risk of unnecessary side effects. ?? Learn more about the ArteraAI #ProstateTest and its benefits for your practice: https://heyor.ca/VXdt21

#ArteraAI is #hiring a Software Engineer to work on our data platform. This role will work with a team of engineers who develop tools and services to improve developer experience, productivity, and more. Are you a self-starter with an interest in building systems that have solid monitoring and observability capabilities? Apply today: https://heyor.ca/rfN6AG

Artera is excited to share details about the new Prostate IQ Clinical Trial, led by renowned institutions MD Anderson Cancer Center and Dana-Farber Cancer Institute. This multicenter trial represents a pivotal step forward in personalizing treatment for #prostatecancer patients post-surgery. What makes this trial unique? ??Personalized Treatment: The trial aims to identify which patients benefit most from additional #hormonetherapy and which can safely avoid it, preserving their quality of life. ??Cutting-Edge Science: This is the first trial to use an #ArteraAI test in this context, underscoring the potential to tailor treatment plans to each patient’s unique cancer profile. ??Rigorous Design: Enrolling patients across 10-15 sites, the trial will assess outcomes like progression-free survival, metastasis-free survival, and quality of life over 24 months. Artera remains dedicated to empowering clinicians and patients with insights that improve care while minimizing unnecessary treatment.

The #ArteraAI team is headed to the LUGPA Specialty Networks 2025 Prostate Cancer Academy next week! Stop by to connect with Shauna Lynn Clark, Donald Lenc, and Adele Blackler from our team to learn more about how the ArteraAI Prostate Test is helping patients with localized #prostatecancer.

No two cancer cases are the same. The #ArteraAI Prostate Test helps doctors personalize #cancertreatment by analyzing biopsy images and clinical data to predict therapeutic benefit. This means more tailored care and fewer unnecessary treatments. Discover how our #MMAI architecture makes this possible:

The #ArteraAI team is headed to the ACRO - American College of Radiation Oncology Radiation Oncology Summit next week! Stop by Booth #116 to connect with Michael Chang, Shauna Lynn Clark, and John Benton from our team to learn more about how the ArteraAI Prostate Test is helping patients with localized #prostatecancer. #radonc #ACRO2025 https://heyor.ca/xvF7Ec

Artera’s partnership with Tempus AI is expanding access to AI-driven #prostatecancer care! Inside Precision Medicine shares how the collaboration addresses the critical need for more accurate cancer #prognostics and exemplifies the future of #AI in medicine, where technology bridges the gap between data and lifesaving decisions: